Allard-Chamard, Hugues

Professeur, Faculté de médecine et des sciences de la santé
FMSS Département de médecine

Coordonnées

Courriel


819-821-8000, poste 15261

Diplômes

(2015) Localisation et implication des phospholipases A2 cytosolique et sécrétée dans le contrôle de l’ostéoclastogénèse et des fonctions ostéoclastiques chez l’humain. [Implication of cytosolic and secreted phospholipases A2 in the control of osteoclastogenesis and human osteoclasts’ functions]. Doctorate (Philosophiae Doctor in Pharmacology). Université de Sherbrooke.

(2014) Post-doctorate. Université de Sherbrooke.

(2011) Post-doctorate (Internal medicine). Université de Sherbrooke.

(2011) Doctorate (Medicinae Doctor). Université de Sherbrooke.

(2009) Certificate (3rd cycle Enrichment Microprogram in Research Skills). Université de Sherbrooke.

(2007) Master's non-Thesis (Master in Pharmacology). Université de Sherbrooke.

(2005) Bachelor's (Bachelor’s Degree in Pharmacology). Université de Sherbrooke.

Research Associate (Immunology and Epigenetics). Ragon Institute of MGH, MIT and Harvard.

Titres de compétence

Fellow of the Royal College of Physicians of Canada. Royal College of Physicians and Surgeons of Canada.

NGS Data Analysis Course. Harvard School of Public Health.

Training in bone biopsy and histomorphometry. Centre hospitalier de l'université de Montréal.

Training in optical immunology. Hôpital Maisonneuve-Rosemont.

Expérience académique

(2019) Clinician-scientist - Rheumatologist. Université de Sherbrooke.

(2016) Lecturer for the General Pharmacology class (PHR504). Université de Sherbrooke.

Présentation

Sujets de recherche

Auto-Immune Diseases, Arthritis / Osteo-Arthritis, Bone Diseases, Diseases of the Immune System, Molecular Genetics.

Disciplines de recherche

Rheumatology, Pharmacology, Immunology, Genetics, Molecular Biology.

Mots-clés

Immunology, Epigenetics, IgG4 related disease, Inflammatory arthritis, Primary Immunodeficiency, Memory B cells, Bone metabolism, Osteoclast differentiation and metabolism.

Intérêts de recherche

I am interested in elucidating how immune cell dysfunction leads to the chronicity of rheumatologic diseases and end organs damages. This endeavor lead me to be part of a global effort aiming at characterizing the antigen(s) driving chronic immune activation and plasmablast activation in IgG4-RD. We were able to identify new subsets of auto-reactive activated B cells infiltrating tissu and are currently performing extensive immunophenotyping, repertoire analysis and chromatin characterization to understand their functions and ontology. I am also working with Dr Jocelyn Farmer, on her cohort of more then 180 patients with CVID, to identify, using whole exome sequencing, new monogenic causes of CVID. We then use those discrete genetic alteration as model to understand the fundament of normal lymphocyte development. We are also using the subset of CVID patients developping auto-immune condition to ask how the monogenic defects that we identify were able to lead to a breach in tolerance.

Recherche clinique

Oui

Langues parlées et écrites

Anglais, Français, Espagnol (castillan)

Prix et distinctions

  • (2019) Faculté de medecine et des science de la santé Grant for Fellowship. Université de Sherbrooke. (Prize / Award).
  • (2009) André Lussier Grant for commitment to rheumatology. Centre Hospitalier Univ. de Sherbrooke. (Prize / Award).
  • André Ghibely Grant for Best Grades in the Musculoskeletal Session. Université de Sherbrooke. (Prize / Award).
  • BESC M Grant. Natural Sciences and Engineering Research Council of Canada (NSERC). (Prize / Award).
  • ES M Grant. Natural Sciences and Engineering Research Council of Canada (NSERC). (Prize / Award).
  • Grant for Excellent Grades in Science. Fonds de recherche du Québec - Santé (FRQS). (Prize / Award).
  • Grant for MD PhD Training. Fonds de recherche du Québec - Santé (FRQS). (Prize / Award).
  • Grant for PhD in Priority Research Field (Osteoporosis). Canadian Institutes of Health Research. (Prize / Award).
  • Grant for Research on Inflammatory Arthritis - declined. Canadian Arthritis Network. (Prize / Award).
  • Internal Medicine Program’s Research Day Award. Centre Hospitalier Hôtel-Dieu de Sherbrooke. (Prize / Award).
  • PhD Grant for Student Excellence. Université de Sherbrooke. (Prize / Award).
  • Summer Grant for Trainee in the Musculoskeletal Field. Canadian Institutes of Health Research. (Prize / Award).

Publications

Articles de revue

  • Netravali I, Carriapa A, Yates K, Haining N, Rosenberg I, Allard-Chamard H, Bertocci A, Pillai S,. (2019). 9-O-acetyl sialic acid levels identify committed progenitors of plasmacytoid dendritic cells. Glycobiology, (Published).
  • Allard-Chamard H, Liang P,. (2019). ANCAs. Clinics in Laboratory Medicine, (Accepted).
  • Allard-Chamard H, Mahajan S V,. (2019). Future of immunology laboratory testing. Clinics in Laboratory Medicine, (Accepted).
  • Newman JH, Shaver A, Sheehan JH, Mallal S, Stone JH, Pillai S, Bastarache L, Riebau D, Allard-Chamard H, Stone WM, Perugino C, Pilkinton M, Smith SA, McDonnell WJ, Capra JA, Meiler J, Cogan J, Xing K, Mahajan VS, Mattoo H, Hamid R, Phillips JA. (2019). IgG4-related disease: Association with a rare gene variant expressed in cytotoxic T cells. Mol Genet Genomic Med, e686, 1-8. (In Press).
  • Allard-Chamard H. (2019). Laboratory testing in the context of biologics and cellular therapies, Serological diagnosis of rheumatoid arthritis. Clinics in Laboratory Medicine, (Accepted).
  • Allard-Chamard H, Boire G,. (2019). Serological diagnosis of rheumatoid arthritis. Clinics in Laboratory Medicine, (Accepted).
  • Boire G, Allard-Chamard H,. (2019). The 4-H of Biomarkers: Help, Harm, Hype, Hope, Report on the Dunlop-Dottridge Lecture. The Journal of Rheumatology, 46(7), 758-763. (Published).
  • Farmer RJ, Allard-Chamard H, Sun N, Ahmad M, Bertocchi A, Mahajan S V, Aicher T, Arnold J, Benson M D, Morningstar J, Barmettler S, Yuen G, Murphy JH S, Walter J, Ghebremichael M, Shalek AK, Batista F, Gerszten R, Pillai S,. (2019). The acquisition of extracellular adenosine salvage and a metabolic switch during human transitional to follicular B cell development. Science Signaling, (Revision Requested).
  • Perugino AC, Maehara T, Kaneko N, Mattoo H, Kers J, Allard-Chamard H, Mahajan S V, Liu H, Murphy S, Zhang X, Ghebremichael M, Tuncay Y, Della Torre E, Lang L, Montesi S, Renfro-Wallace Z, Fox D, Yosef N, Lafyatis R, Stone H J, Khanna D, and Pillai S,. (2019). Tissue-infiltrating SLAMF7+ CD4+ cytotoxic T cells and endothelial cell apoptosis in systemic sclerosis. Science Translational Medicine, (Submitted).
  • Perugino CA, AlSalem SB, Mattoo H, Della-Torre E, Mahajan V, Ganesh G, Allard-Chamard H, Wallace Z, Montesi SB, Kreuzer J, Haas W, Stone JH, Pillai S. (2018). Identification of galectin-3 as an autoantigen in patients with IgG4-related disease. J Allergy Clin Immunol, S0091-6749(18), 30768-1. DOI. (Published).
  • Allard-Chamard H, and Pillai S,. (2017). Turning Charon around on the Styx?. Science immunology, 2(13), V. DOI. (Published).
  • Allard-Chamard H, Dufort P, Haroun S, De Brum-Fernandes A. J. (2014). Cytosolic phospholipase A2 and eicosanoids modulate life, death and function of human osteoclasts in vitro. Prostaglandins, Leukotrienes and Essential Fatty Acids, 90(4), 117-123. (Published).
  • Allard-Chamard H, Haroun S, De Brum-Fernandes A. J. (2014). Secreted phospholipase A2 type II is present in Paget's disease of bone and modulates osteoclastogenesis, apoptosis and bone resorption of human osteoclasts independently of its catalytic activity in vitro. Prostaglandins, Leukotrienes and Essential Fatty Acids, 2(90), 39-45. (Published).
  • Mathurin K, Gallant M. A, Germain P, Allard-Chamard H, Brisson J, Iorio-Morin C, De Brum-Fernandes A. J, Caron M. G, Laporte S. A, Parent J. L et al. (2011). An interaction between L-prostaglandin D synthase and arrestin increases PGD2 production. Journal of Biological Chemistry, 286(4), 2696-2706. (Published).
  • Allard-Chamard H. (2010). Rôles de l’ostéoclaste dans l’érosion péri-articulaire de la polyarthrite rhumatoïde. Espace-Recherche, 2, 10-6. (Published).
  • Allard-Chamard H. (2008). Situation des MD MSc/PhD au Canada et au Québec. Espace-Recherche, 1, 6-8. (Published).
  • Hackett J. A, Allard-Chamard H, Sarrazin P, De Fatima Lucena M, Gallant M. A, Fortier I, Nader M, Parent J. L, De Brum-Fernandes A. J. (2006). Prostaglandin production by human osteoclasts in culture. The Journal of rheumatology, 33(7), 1320-1328. (Published).

Chapitres de livre

  • Allard-Chamard H, Debiais F, Roux S,. (2019). Malignant Bone Diseases (as they apply to Rheumatic Diseases). J. Da Silva, F. Buttgereit, M.A. Cimmino, F. Lioté, & T. O’Neill EULAR Textbook on Rheumatic Diseases (4th Edition, To come). BMJ Group. (Submitted).
  • Allard-Chamard H, Debiais F, Roux S,. (2018). Malignant Bone Diseases (as they apply to Rheumatic Diseases). Johannes WJ Bijlsma Eric Hachulla EULAR Textbook on Rheumatic Diseases (3rd Edition, 1004-1037). United Kingdom : BMJ Group. (Published).

Manuels

  • Allard-Chamard H, Débiais F, Roux S,. (2018). EULAR Online course on Rheumatic Diseases ( Chapter 38c ). (Published).
  • Allard-Chamard H, Débiais F, Roux S,. (2018). EULAR Online course on Rheumatic Diseases ( Discussion in depth : Pharmacology indude osteonecrosis of the jaws ). (Published).

Ressources en ligne

  • Allard-Chamard H, Débiais F, Roux S,. (2018). EULAR Online course on Rheumatic Diseases Module 38c. Site Web.

Autres contributions

Cours enseignés

  • General pharmacology. PHR 504. (2015-03-19). Niveau : Undergraduate. (2CR).

Gestion d'évènements

  • Chair. (2020). Top 3 in Rhumatology. (Conference).
  • Chair - Co-Scientific director. (2016). Sherbrooke University joint Rheumato-Geriatry symposium. (Seminar).
  • Session Chairman. (2015). Sherbrooke University Internal Medicine Department Research Symposium. (Seminar).

Activités de collaboration internationale

  • Co-Investigator. (2016-2030). United States. I developed a collaboration with Dr Jocelyn Farmer a clinical immunologist at the Massachusetts General Hospital in Boston to study the genetic basis of immune dysfunction in patients with Primary Immune deficiencies with a focus on CVID. We have an institutional agreement that allows us to share patient specimens bi-directionally across the border to perform complementary analyses and explore the signaling defects leading to both immunodeficiency and autoimmunity in this cohort of patients. The cohort is now composed of over 200 patients and family members and has already catalyzed a broad research program and led to the identification of the dysfunctional immune cell subsets in patients with mutations in phosphoinositide 3-kinases (PIK3CD), Nuclear factor-?B1 (NFKB1) and Cytotoxic T-lymphocyte-associated protein 4 (CTLA4). This productive collaboration is rapidly growing and we plan to extend recruitment to both Canada and United-States, including patients with autoimmunity.

Présentations

  • (2019). How could genetics help understanding rheumatic diseases; The experience of a cohort of patients with commun variable immunodeficiency caused by monogenetic defects. Centre d’ostéoporose et de rhumatologie de Québec. Québec, Canada.
  • (2019). Osteoclast Precursor Assessment In Rheumatoid Arthritis: The In Vitro Osteoclast Differentiation in Arthritis (IODA) study. ASBMR 2019. Orlando, United States.
  • (2019). Primary immune deficiency as a tool in understanding the mechanisms regulating self tolerance in human. Axe Maladies Infectieuses et Immunitaires. Quebec, Canada.
  • (2019). The adenosine salvage pathway is induced in late human transitional 3 B cells and facilitates their metabolic reprograming toward a mature follicular B cell fate. Federation of Clinical Immunology Societies 2019. Boston, United States.
  • (2018). Adenosine salvage inhibits mTORC1 signaling and metabolically reprograms transitional human B cells towards a follicular fate. Ragon immunology retreat. Lincoln, NH, United States.
  • Dr Jocelyn Farmer. (2018). Novel mutation in the p85 regulatory subunit of PI3K-delta induce classic PI3K-delta hyper activation syndrome and bloc B cells differentiation at the transitional stage. Primary immune deficiency PID diagnostics school. United States.
  • (2016). A challenging osteoporosis case in a patient suffering from type 2 neurofibromatosis. Montréal University’s bone club. Montréal, Canada.
  • (2016). Challenging cases at the frontier of rheumatology and geriatrics. Sherbrooke University's joint Rheumato-Geriatry symposium. Magog-Orford, Canada.
  • Dr Ariel Masseto. (2016). Choosing wisely Canada-Rheumatology. Sherbrooke's Medical Student networking session. sherbrooke, Canada.
  • Dr Michael Mayette. (2016). Discussion about a complex and rare case of lupus. Joint internal and rheumatology meeting of Sherbrooke University. Sherbrooke, Canada.
  • (2016). Inflammatory myositis of the physiatrist. Montréal University’s Physiatry service weekly meeting. Montréal, Canada.
  • (2016). Microcrystalline arthritis of the elderly. Sherbrooke University's joint Rheumato-Geriatry symposium. Magog-Orford, Canada.
  • (2016). Optical immunology for the rheumatologist. Sherbrooke University’s Rheumatology service meeting. Sherbrooke, Canada.
  • (2016). Osteoclast microRNA profiling in erosive rheumatoid arthritis. ASBMR. Atlanta, United States.
  • (2016). Osteoclast microRNA profiling in erosive rheumatoid arthritis. ASBMR 2016. Atlanta, United States.
  • (2016). Osteoclastogenesis as a predictor of articular damage in rheumatoid arthritis. Sherbrooke University’s Rheumatology service meeting. Sherbrooke, Canada.
  • (2015). Choosing wisely Canada recommendation : Implication for the rheumatologist. Sherbrooke University’s Rheumatology service meeting. Sherbrooke, Canada.
  • (2015). Could ultrasonography of major salivary glands distinguish primary Sjögren syndrome from other connective tissue disorder associated with sicca. Sherbrooke University’s Rheumatology service meeting. Sherbrooke, Canada.
  • (2015). Hematological Manifestation of Sjögren disease. McGill University’s Rheumatology service weekly meeting. Montréal, Canada.
  • (2015). Neonatal Lupus indentification and management. Sherbrooke University’s Rheumatology service meeting. Sherbrooke, Canada.
  • (2015). Pediatric anti-phospholipid syndrome. McGill pediatric rheumatology service weekly meeting. Montréal, Canada.
  • (2015). mTORC inhibition in the phospholipid syndrome, a new therapeutic opportunity?. Sherbrooke University’s Rheumatology service meeting. Sherbrooke, Canada.
  • Dr Nimrit Dhillon. (2014). Case presentation, Polymyalgia rheumatic mimickers. Toronto University’s rheumatology services weekly meeting. Toronto, Canada.
  • (2014). Phospholipase A2 roles in osteoclastic metabolism regulation. Sherbrooke University’s Rheumatology service meeting. Sherbrooke, Canada.
  • (2014). Tofcitinib use for the treatment of rheumatoid arthritis. Chicoutimi Hospital’s Internal medicine department. Chicoutimi, Canada.
  • (2014). Transplant of autologous hematopoetic stem cells in the treatment of diffuse systemic sclerosis. Sherbrooke University’s Haematology and Oncology service. Sherbrooke, Canada.
  • (2013). Hyperoesinophilic syndrome management. Charles LeMoyne internal medicine half day. Greenfield park, Canada.
  • Maxime Gallant. (2013). Influence of prostaglandin D2 on mesenchymal stem cell fate. ASBMR 2013. Baltimore, United States.
  • (2013). Journal club : Kim, Hye-Jin, et al. "Effect of statin on progression of symptomatic intracranial atherosclerosis." The Canadian Journal of Neurological Sciences 39.06 (2012): 801-806. Sherbrooke University’s Neurology service weekly meeting. Sherbrooke, Canada.
  • Dr Dany Burk. (2013). Pay for performance system. Conference for 1st to 5th year resident in internal medicine. Sherbrooke, Canada.
  • (2013). Renal manifestations of Sjögren disease. Sherbrooke University’s Nephrology service meeting. Sherbrooke, Canada.
  • (2013). cPLA2 - a key component of OCs’ biology. Journée scientifique des résidentes et résidents du département de médecine FMSS. Sherbrooke, Canada.
  • (2012). Gastrointestinal manifestation of henoch-schonlein purpura. Sherbrooke University’s Gastroenterology service weekly meeting. Sherbrooke, Canada.
  • (2012). Journal club : Presenting the RAVE study. Victoriaville Hospital’s Internal medicine department weekly meeting. Victoriaville, Canada.
  • (2012). Osteocalcin-leptin axis. Sherbrooke University’s Endocrinology service weekly meeting. Sherbrooke, Canada.
  • (2012). Plasmapheresis indication in systemic vasculitis. Charles LeMoyne Rheumatology service weekly meeting. Greenfield park, Canada.
  • (2012). Remitting seronegative symmetrical synovitis with pitting oedema diagnostic and management. Victoriaville Hospital’s Internal medicine department weekly meeting. Victoriaville, Canada.
  • (2012). Superior veina cava syndrome. Sherbrooke University’s Respirology service weekly meeting. Sherbrooke, Canada.
  • (2011). Choosing between regular and intensive insulinotherapy at the intensive care unit. Conference for 1st to 5th year resident in internal medicine. Sherbrooke, Canada.
  • (2011). Cutaneous vasculitis. Chicoutimi Hospital’s Internal medicine department. Chicoutimi, Canada.
  • (2011). Targeted investigation of Amaurosis Fugal for the first line physician. Saint-Hyacinthe General practitioner team office. Saint-Hyacinthe, Canada.
  • (2010). Children’s anemia investigation. Saint-Jean sur Richelieu’s Paediatric department. Saint-Jean sur Richelieu, Canada.
  • (2010). Cirrhosis in adult: Etiologic investigation. Chicoutimi Hospital’s Internal medicine department weekly meeting. Chicoutimi, Canada.
  • (2010). Implication of the phospholipid syndrome for the obstetrician. Edmonton’s Obstetrics and Gynaecology Department. Edmonton, Canada.
  • (2009). Cytosolic phospholipase A2 pharmacology in human osteoclasts. Association francophone pour le savoir. Ottawa, Canada.
  • (2009). Ex vivo apoptosis resistance and increased osteoclastic activity in osteoclasts from osteoarthritis patients. Journée Phare. Sherbrooke, Canada.
  • (2009). Increase in osteoclastogenesis in rheumatoid arthritis patient cohort. Journée Phare. Sherbrooke, Canada.
  • (2009). Osteoclastogenesis in rheumatoid arthritis, new insights in disease severity. Présentation du Centre de recherche clinique pour l’axe ostéo-articulaire. Sherbrooke, Canada.
  • (2009). Osteoclastogenesis modulation in rheumatoid arthritis patients. Journée de la recherche de la Faculté de médecine et des sciences de la santé de l’Université de Sherbrooke. Sherbrooke, Canada.
  • (2009). Roles of phospholipase A2 in the control of bone metabolism; new potential clinical implications. Sherbrooke University’s Rheumatology service. Sherbrooke, Canada.
  • (2008). Bone functions of sPLA2. Journée de la recherche de l’Université de Sherbrooke. Sherbrooke, Canada.
  • (2008). Identification of a Novel Interaction Between Arrestin-3 and LDPDS. Canadian Arthritis Network’s 2008 Annual Scientific Conference. Toronto, Canada.
  • (2008). Implication of Cytosolic Phospholipase A2 in the Control of Osteoclast Metabolism. International Conference on Bone and Mineral Research. Beijing, China.
  • (2008). Increased Osteoclastogenesis in Patients with Rheumatoid Arthritis. Canadian Rheumatology Association meeting. Mont-Tremblant, Canada.
  • (2008). Localisation and Function of Phospholipase A2 in Bone Cells. Canadian Rheumatology Association Conference and Annual Meeting. Mont-Tremblant, Canada.
  • (2008). Pharmacology of the Soluble Phospholipase A2 in the Life and Death of Osteoclasts. Canadian Arthritis Network’s 2008 Annual Scientific Conference. Toronto, Canada.
  • (2008). cPLA2 in the Life and Death of Osteoclasts. Young Investigators Forum. Toronto, Canada.
  • (2006). Prostaglandins as Autacoids in Human Osteoclasts. Société canadienne de rhumatologie. Toronto, Canada.
  • (2005). Prostaglandin Production by Human Osteoclasts. 11th Canadian Connective Tissue Conference. Montréal, Canada.

Les informations disponibles dans la base de données Expertus sont tirées du CV commun canadien.